Navigation Links
Two-Year Data Show Investigational Drug Liraglutide More Effective at Lowering Blood Sugar Than Glimepiride: Oral 162
Date:6/7/2009

reated group. The most common gastrointestinal-related adverse events were nausea, diarrhea and vomiting, and most were transient. Other adverse events reported included flu-like symptoms.

About LEAD(TM) (Liraglutide Effect and Action in Diabetes)

The LEAD(TM) program comprises five randomized, controlled, double-blinded studies plus one open-label head-to-head study against exenatide and involved more than 4,000 patients with type 2 diabetes in 40 countries.

About Liraglutide

Once-daily liraglutide is the first human glucagon-like peptide-1 (GLP-1) analog developed for the treatment of type 2 diabetes. Liraglutide works by stimulating the release of insulin only when blood sugar levels are high. Weight loss with liraglutide is attributed to the fact that it slows gastric emptying and leads to increased satiety after meals. Liraglutide is naturally broken down in the body and does not require renal excretion.

On May 23, 2008, Novo Nordisk submitted a New Drug Application to the Food and Drug Administration (FDA) in the U.S., as well as a marketing authorization application to the European Medicines Agency (EMEA), for the approval of liraglutide for the treatment of people with type 2 diabetes. A New Drug Application was also submitted for approval in Japan on July 14, 2008.

On April 23, 2009, Novo Nordisk announced that the Committee for Medicinal Products for Human Use (CHMP) under the EMEA adopted a positive opinion, recommending marketing authorization of liraglutide for treatment of type 2 diabetes in Europe.

In the U.S., a regulatory decision is pending.

Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as hemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pha
'/>"/>

SOURCE Novo Nordisk
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Two-Year Data Reinforce Effect of ACTEMRA(R) (tocilizumab) in Inhibiting Progression of Joint Damage and Improving Physical Function in Rheumatoid Arthritis Patients
2. Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients With Multiple Sclerosis
3. The Lancet Publishes Two-Year Results of Abbotts Fully Bioabsorbable Drug Eluting Stent
4. Circulation Publishes Pivotal Two-Year Results On XIENCE V(TM) Drug Eluting Stent
5. Two-Year Follow-Up Data Demonstrates Preservation of Adequate Mitral Valve Area in Patients Treated with the MitraClip(R) System
6. XTENT Announces Positive Two-Year CUSTOM I and One-Year CUSTOM II Trial Data for Novel Drug-Eluting Stent System
7. Two-Year Outcomes From Large Head-to-Head Clinical Trial Indicate Similar Safety Profile in Diabetic Patients for Cypher(R) Sirolimus-Eluting Coronary Stent and Taxus Stent
8. Lilly Announces Positive Phase II Data on Investigational Medicine for Patients with Type 2 Diabetes
9. Investigational Cancer Drug BSI-201 Showed Clinical Benefit in 62% of Patients with Triple-Negative Metastatic Breast Cancer and Significantly Prolonged Survival
10. Intercell AG Announces First Subject Enrolled in a Phase II Trial for the Further Development of Its Investigational Vaccine Enhancement Patch to Improve Pandemic Influenza Prevention in Collaboration With U.S. Department of Health and Human Services (HHS
11. Medarex Announces Allowance of Investigational New Drug Application for Wholly-Owned Fully Human Anti-CXCR4 Antibody, MDX-1338
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced ... Chief Executive Officer of Neurocrine Biosciences, will be presenting at ... Conference in Boston.   The live presentation takes ... / 8:20 a.m. Pacific Time.  The presentation will be webcast ... http://www.neurocrine.com . If you are unable to ...
(Date:5/23/2013)... , May 23, 2013  MGC Diagnostics Corporation ... global medical technology company, today scheduled a conference call ... of fiscal year 2013, ended April 30, 2013. The ... May 30, 2013. The Company will report financial results ... the markets close on Thursday, May 30, 2013. ...
(Date:5/23/2013)... SAN DIEGO , May 23, 2013 /PRNewswire/ ... the prostate cancer treatment continuum was highlighted prominently ... the American Urological Association (AUA), in San Diego.  ... invasive high intensity focused ultrasound (HIFU) technology, the ... localize disease, and for urologists to consider minimally ...
Breaking Medicine Technology:MGC Diagnostics Corporation to Report Second Quarter Fiscal 2013 Financial Results on Thursday, May 30, 2013 2Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 2Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 3Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 4Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 5Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 6
(Date:5/25/2013)... Center, FL (PRWEB) May 25, 2013 Absolute ... one of many of the NALA’s businesses throughout the country ... Amshel chose to participate in the nationwide event as he ... a Lieutenant Colonel in the Army. He said, “I wanted ... the community I serve, but I live here too.” , ...
(Date:5/25/2013)... 2013 The latest report from ... bowel syndrome (IBS) to bloating, constipation, diarrhea and ... long-lasting, embarrassing, frustrating and difficult health issues to ... health have provided a cure for these ... contributing to digestive health issues, a healthy diet ...
(Date:5/25/2013)... (PRWEB) May 25, 2013 According ... Emergency Management Market, 2013–2018", published by MarketsandMarkets is ... a CARC of 5.54% which analyzes and studies ... North America, Europe, Asia, and Rest of the ... Market Data Tables , 87 Figures ...
(Date:5/25/2013)... 25, 2013 According to world-renowned scholars, ... and powerful women that ever lived. Cleopatra’s legendary beauty ... of the most powerful men in her time. Cleopatra ... to keep her skin glowing and fresh, from her ... wax, maringa oil and cyprus grass. , Cleopatra was ...
(Date:5/25/2013)... CA (PRWEB) May 25, 2013 IBISWorld estimates ... grow at an average annual rate of 28.7% to $1.0 ... 17.9% in 2013. From 2002 and 2008, no new cell ... Culbert, causing relatively modest growth during that period. In the ... approved six new products. This factor contributed to the industry's ...
Breaking Medicine News(10 mins):Health News:Dr. Craig Amshel of Absolute Surgical Specialists Offering Bowel Prep During the Shop Local for a Cause Event 2Health News:Natural Foods For Digestive Health Report and Video Published by BetterDigestion.org 2Health News:Homeland Security Market to Reach $544.02 Billion by 2018 at a CARC of 5.54% - New Report by MarketsandMarkets 2Health News:Homeland Security Market to Reach $544.02 Billion by 2018 at a CARC of 5.54% - New Report by MarketsandMarkets 3Health News:Homeland Security Market to Reach $544.02 Billion by 2018 at a CARC of 5.54% - New Report by MarketsandMarkets 4Health News:The Cleopatra Lift - A New Non Surgical Option to Aging Offered by Vancouver Physician 2Health News:The Cleopatra Lift - A New Non Surgical Option to Aging Offered by Vancouver Physician 3Health News:Slow Healing: Cell Therapy in the US Industry Market Research Report Now Available from IBISWorld 2Health News:Slow Healing: Cell Therapy in the US Industry Market Research Report Now Available from IBISWorld 3
... both lauds and supports the Institute of Medicine,s ... Education, and Practice . The recommendations will ... judgment and preserving public trust in medicine. ... of Physicians Foundation and the European Federation of ...
... team has made the world-first discovery a ,pied piper, ... molecules into the nucleus of the cell, and could ... cancers as well as leukemia. , Uncovered by two ... Research (WAIMR) led by Associate Professor Evan Ingley and ...
... April 28 Gene Network Sciences, Inc. today announced ... Wyeth Research & Development and a leader in pharmaceutical ... as President of Wyeth Research & Development in 2008, ... had joined Wyeth in November 2000 and has been ...
... BANNOCKBURN, Ill., April 28 Healthy Life Laboratories has announced ... use by diabetes patients and healthcare professionals - the ... of its kind for use on iPhone and ... better understand the relationship between blood glucose and hemoglobin A1c.Maintaining ...
... Combat Spread of VirusesLAS VEGAS, April 28 Skinvisible, ... company of patented skincare and medical dermatology products, has ... in killing the H1N1 swine flu virus found in ... studies with Skinvisible,s Hand Sanitizer Lotion; DermSafe. ...
... Institute of Allergy and Infectious Diseases (NIAID), part ... China,s Henan Provincial Bureau of Health will meet ... an implementation arrangement intended to foster research on ... multidrug-resistant tuberculosis (MDR TB). The Henan Provincial Bureau ...
Cached Medicine News:Health News:Statement by Christine K. Cassel, MD, President and CEO of the ABIM Foundation on the Institute of Medicine Report: Conflict of Interest in Medical Research, Education, and Practice 2Health News:WA discovery a key to blood cell development 2Health News:Gene Network Sciences Names Former Wyeth President of R&D Robert Ruffolo to SAB 2Health News:Gene Network Sciences Names Former Wyeth President of R&D Robert Ruffolo to SAB 3Health News:Healthy Life Laboratories Announces Hemoglobin A1c iPhone Application 2Health News:Skinvisible's DermSafe(R) Hand Sanitizer Kills Swine Flu Virus 2Health News:Skinvisible's DermSafe(R) Hand Sanitizer Kills Swine Flu Virus 3Health News:NIAID and Chinese officials sign agreement to foster TB research in China's Henan province 2
... Our breadth of infectious disease ELISA ... field. With standard assay protocols for faster ... Disease ELISA products provide increased reliability and ... includes antibody detection assays for a wide ...
Inquire...
... autoimmune testing feature single-well ANA screen and ... reflex tests including dsDNA, and 6 individual ... (La), Scl-70 and Jo-1. In addition, our ... of products for Cardiolipins (IgA, IgG, IgM), ...
... for autoimmune testing feature single-well ANA screen ... specific reflex tests including dsDNA, and 6 ... SS-B (La), Scl-70 and Jo-1. In addition, ... line of products for Cardiolipins (IgA, IgG, ...
Medicine Products: